source
- Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug marketThe American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
- Tango to launch Phase 3 trial in pancreatic cancer after promising combo resultsTango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…